MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) has launched its lead commercial software Intox AI for validation and testing of intoxication and fatigue.
Intox AI enables new analytical capabilities to detect cocaine, cannabis, alcohol, psychedelics, narcotic use and human fatigue non-invasively, from voice.
In a statement, Justin Hanka, CEO of MindBio, commented, “The launch of Intox AI is a significant advancement for drug and alcohol testing across a range of substances that affect human performance and safety. The company is on track to deliver its first prototype testing kiosks shortly and is delighted the core software is ready for testing and validation.”
